CN1551880A - 阿昔洛韦缬氨酸酯盐酸盐的晶型 - Google Patents

阿昔洛韦缬氨酸酯盐酸盐的晶型 Download PDF

Info

Publication number
CN1551880A
CN1551880A CNA028174143A CN02817414A CN1551880A CN 1551880 A CN1551880 A CN 1551880A CN A028174143 A CNA028174143 A CN A028174143A CN 02817414 A CN02817414 A CN 02817414A CN 1551880 A CN1551880 A CN 1551880A
Authority
CN
China
Prior art keywords
valacyclovir hydrochloride
type
acyclovir
solvent
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028174143A
Other languages
English (en)
Chinese (zh)
Inventor
S��ά˹
S·维策尔
��ϣ÷��
J·阿伦希梅
�ķ-ϣ����лķ
V·尼达姆-希尔德谢姆
���Ļ�
B·-Z·多利茨基
M·Y·埃廷格尔
ά
M·于泽福维赫
G·A·尼斯奈维克
�Ʒ�
B·佩尔特斯科夫
B·蒂辛
D·布拉斯贝格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN1551880A publication Critical patent/CN1551880A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CNA028174143A 2001-09-07 2002-09-06 阿昔洛韦缬氨酸酯盐酸盐的晶型 Pending CN1551880A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US31785001P 2001-09-07 2001-09-07
US60/317,850 2001-09-07
US34227301P 2001-12-21 2001-12-21
US60/342,273 2001-12-21
US38650502P 2002-06-05 2002-06-05
US60/386,505 2002-06-05
US40383802P 2002-08-14 2002-08-14
US60/403,838 2002-08-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN 200510022996 Division CN1789266A (zh) 2001-09-07 2002-09-06 阿昔洛韦缬氨酸酯盐酸盐的晶型

Publications (1)

Publication Number Publication Date
CN1551880A true CN1551880A (zh) 2004-12-01

Family

ID=27502150

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028174143A Pending CN1551880A (zh) 2001-09-07 2002-09-06 阿昔洛韦缬氨酸酯盐酸盐的晶型

Country Status (16)

Country Link
US (2) US6849736B2 (enExample)
EP (1) EP1436295A4 (enExample)
JP (2) JP5043286B2 (enExample)
KR (1) KR100774271B1 (enExample)
CN (1) CN1551880A (enExample)
CA (1) CA2457835A1 (enExample)
CZ (1) CZ2004446A3 (enExample)
HR (1) HRP20040321A2 (enExample)
HU (1) HUP0500753A3 (enExample)
IL (1) IL160721A0 (enExample)
IN (2) IN2004MU00133A (enExample)
MX (1) MXPA04002192A (enExample)
NO (1) NO20041449L (enExample)
PL (1) PL374179A1 (enExample)
SK (1) SK1592004A3 (enExample)
WO (1) WO2003022209A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
MX242714B (es) * 2001-11-14 2006-12-15 Teva Pharma Sintesis y purificacion de valaciclovir.
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20050070711A1 (en) * 2002-10-16 2005-03-31 Igor Lifshitz Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1633753A1 (en) * 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
CA2527708A1 (en) * 2003-06-02 2005-01-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
ES2246034T3 (es) * 2003-12-09 2006-02-01 Helm Ag Formulacion farmaceutica de valaciclovir.
JP2008504255A (ja) * 2004-06-30 2008-02-14 テバ ファーマシューティカル インダストリーズ リミティド 結晶塩酸バラシクロビル中の残留アルコールを低減する方法
WO2006035452A1 (en) * 2004-09-27 2006-04-06 Matrix Laboratories Ltd Novel pseudomorph of valaciclovir hydrochloride
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US7872075B2 (en) * 2005-10-07 2011-01-18 Exxonmobil Chemical Patents Inc. Peroxide-cured thermoplastic vulcanizates and process for making the same
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
GB201222287D0 (en) * 2012-12-11 2013-01-23 Ct For Process Innovation Ltd Methods for making active crystalline materials
CR20160222U (es) 2013-11-15 2016-08-26 Akebia Therapeutics Inc Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
KR20200022712A (ko) 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
ATE199719T1 (de) * 1993-06-10 2001-03-15 Rolabo Sl Verfahren zur herstellung von aminosäureester von nukleosid analogen
US5856481A (en) * 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
WO1997025989A1 (en) * 1996-01-19 1997-07-24 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US6040446A (en) * 1996-01-26 2000-03-21 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
AU1592897A (en) * 1996-01-26 1997-08-20 F. Hoffmann-La Roche Ag Process for preparing purine derivatives
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
MX242714B (es) * 2001-11-14 2006-12-15 Teva Pharma Sintesis y purificacion de valaciclovir.
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
AU2003289995A1 (en) * 2002-12-09 2004-06-30 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
EP1633753A1 (en) * 2003-05-30 2006-03-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process

Also Published As

Publication number Publication date
KR100774271B1 (ko) 2007-11-08
MXPA04002192A (es) 2005-02-17
JP2012162565A (ja) 2012-08-30
EP1436295A4 (en) 2007-07-11
JP5043286B2 (ja) 2012-10-10
IN2004MU00133A (enExample) 2005-04-29
US20050187229A1 (en) 2005-08-25
HUP0500753A3 (en) 2006-05-29
US6849736B2 (en) 2005-02-01
IL160721A0 (en) 2004-08-31
CA2457835A1 (en) 2003-03-20
CZ2004446A3 (cs) 2005-01-12
NO20041449L (no) 2004-04-06
SK1592004A3 (sk) 2005-03-04
WO2003022209A3 (en) 2003-11-27
JP2005526694A (ja) 2005-09-08
EP1436295A2 (en) 2004-07-14
HUP0500753A2 (hu) 2005-11-28
US20030114470A1 (en) 2003-06-19
IN2006MU00429A (enExample) 2007-08-17
HRP20040321A2 (en) 2004-08-31
WO2003022209A9 (en) 2004-04-08
PL374179A1 (en) 2005-10-03
WO2003022209A2 (en) 2003-03-20
KR20040036932A (ko) 2004-05-03

Similar Documents

Publication Publication Date Title
CN1551880A (zh) 阿昔洛韦缬氨酸酯盐酸盐的晶型
CN1040761C (zh) 含乙基膦酸酯侧链的稠合含氮杂环衍生物含有它们的药物组合物及其应用
CN1245974C (zh) 卡维地洛
CN1213047C (zh) 酪氨酸蛋白激酶syk的嘌呤衍生物抑制剂
CN1658842A (zh) 利塞膦酸钠的新多晶型物和假多晶型物
CN1675177A (zh) 莫达非尼多晶型
CN1204143C (zh) EtO2C－CH2－(R)Cgl－Aze－Pab－OH的晶形
CN100338040C (zh) 黄嘌呤氧化酶抑制化合物
CN1560035A (zh) 5－羟基吲哚－3－羧酸脂类衍生物
CN1094056A (zh) N-氧羰基取代的5′-脱氧-5-氟胞苷衍生物
CN1125445A (zh) 具有p.de-iv抑制活性的新型化合物
CN1516699A (zh) 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的多晶型物
CN1133642C (zh) 核苷5’-硫代磷酰氨基酸酯化合物
CN1922179A (zh) 盐酸伐昔洛韦的结晶形式
CN1160402A (zh) 用作pnp抑制剂的嘌呤和鸟嘌呤化合物
CN1681507A (zh) 新的螺稠合喹唑酮和它们作为磷酸二酯酶抑制剂的用途
CN1589256A (zh) 盐酸舍曲林的新多晶型物和含有它们的组合物,制备盐酸舍曲林多晶型物和无定形物的新方法
CN101052631A (zh) 结晶霉酚酸钠
CN1231472C (zh) 嘧啶无环核苷衍生物、其制备方法及其用途
CN1482118A (zh) 新颖的5－羟基－3－羧酸酯吲哚类衍生物及其制备方法
CN1084178A (zh) 具抗病毒和抗癌活性的2′-脱氧-2′，2′-二氟(2，6，8-取代的)嘌呤核苷以及中间体
CN101068533A (zh) 含有抗成核剂的药物组合物
CN1665504A (zh) 新晶型的加替沙星
CN1107843A (zh) 二氢化茚衍生物和其制法及合成该衍生物的中间体
CN1066146C (zh) 茶碱衍生物治疗和预防休克状态的用途,新的黄嘌呤衍生物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication